Literature DB >> 1703044

The molecular basis of interstitial pulmonary fibrosis caused by antineoplastic agents.

J S Lazo1, D G Hoyt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1703044     DOI: 10.1016/0305-7372(90)90042-e

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  6 in total

Review 1.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 2.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Fibroblasts from patients with idiopathic pulmonary fibrosis are resistant to cisplatin-induced cell death via enhanced CK2-dependent XRCC1 activity.

Authors:  Jintaek Im; Richard Seonghun Nho
Journal:  Apoptosis       Date:  2019-06       Impact factor: 4.677

4.  Direct leukocyte migration across pulmonary arterioles and venules into the perivascular interstitium of murine lungs during bleomycin injury and repair.

Authors:  Ping M Wang; Diane L Kachel; Mark F Cesta; William J Martin
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 5.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

6.  A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross.

Authors:  Richard Gelinas; Elissa J Chesler; Daphne Vasconcelos; Darla R Miller; Yue Yuan; Kai Wang; David Galas
Journal:  Pharmgenomics Pers Med       Date:  2011-07-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.